Drug Trial Radar · NCT07720284
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
915
Planned (sponsor's estimate)
Start
Jul 16, 2026
Primary completion
Sep 11, 2030
Study completion Nov 23, 2032
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Jul 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Purpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after radical resection. Study details: Duration: \~78 months (6.5 years) from FSI to last subject visit Treatment length: up to \~12 months, depending on randomized arm Visit frequency: every 3 weeks in Arms 1 and 2; every 2-4 weeks per SoC in Arm 3
Conditions
- High-risk Muscle Invasive Urothelial Carcinoma
Interventions
Dato-DXdDrug
Dato-DXd is an ADC comprised of a recombinant humanised anti-TROP2 IgG1 mAb, MAAP-9001a, which is covalently conjugated via a cleavable drug-linker, MAAA1162a (the complex of MAAA-1181a and a maleimide tetrapeptide linker), using thioether bonds to the topoisomerase I inhibitor DXd.
RilvegostomigDrug
Rilvegostomig is a monovalent, bispecific, humanised, IgG1 mAb engineered with an Fc domain that carries a triple mutation (L234F/L235E/P331S) designed to reduce Fc-mediated effector functions. Rilvegostomig contains 2 distinct paratopes that bind to human TIGIT and PD-1 and inhibit binding to their respective immuno-suppressive ligands.
DurvalumabDrug
A fully human monoclonal antibody that blocks the PD-L1 checkpoint to restore anti-tumor T-cell activity. Durvalumab is approved for Muscle invasive bladder cancer (MIBC) as perioperative regime.
NivolumabDrug
A fully human monoclonal antibody against PD-1, promoting anti-tumor immunity. Approved across many malignancies such as melanoma, NSCLC, renal cell carcinoma, Hodgkin lymphoma, hepatocellular carcinoma, and colorectal cancer (dMMR/MSI-H), often alone or with ipilimumab. It's used in several cancers, notably unresectable stage III non-small cell lung cancer after chemoradiation and extensive-stage small cell lung cancer in combination regimens, among others, and is also approved for patients with muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence in the adjuvant setting.
PembrolizumabDrug
A humanized monoclonal antibody targeting PD-1, enhancing T-cell-mediated immune responses against tumors. Indications span multiple cancers including melanoma, NSCLC, head and neck squamous cell carcinoma, urothelial carcinoma, MSI-H/dMMR tumors, and more.
Enfortumab vedotinDrug
An antibody-drug conjugate (ADC) comprised of a fully human anti-Nectin-4 IgG1 monoclonal antibody, linked via a protease-cleavable maleimide-based linker to the microtubule-disrupting agent monomethyl auristatin E (MMAE), which is conjugated through thioether bonds. Upon binding to Nectin-4-expressing cells, the ADC is internalized and releases MMAE, leading to disruption of microtubule dynamics and subsequent tumor cell death. Enfortumab vedotin is approved in urothelial cancers.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate the superiority of Dato-DXd + rilvegostomig (Arm 1) relative to SoC (Arm 3) by assessment of disease-free survival (DFS) (based on Investigator assessments).Time frame: From randomisation until disease recurrence as assessed by investigator or death due to any cause (anticipated to be up to 49 months after the first subject in).
Locations
160 sites in 16 countries. Site status is shown where the registry gives one.
Research Site
Hot Springs, Arkansas · Not yet recruiting
Research Site
Little Rock, Arkansas · Not yet recruiting
Research Site
Little Rock, Arkansas · Not yet recruiting
Research Site
San Francisco, California · Not yet recruiting
Research Site
Chicago, Illinois · Withdrawn
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Kansas City, Missouri · Not yet recruiting
Research Site
Lincoln, Nebraska · Not yet recruiting
Research Site
Omaha, Nebraska · Not yet recruiting
Research Site
Albany, New York · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Myrtle Beach, South Carolina · Not yet recruiting
Research Site
Nashville, Tennessee · Not yet recruiting
Research Site
Dallas, Texas · Not yet recruiting
Research Site
Falls Church, Virginia · Not yet recruiting
Research Site
Seattle, Washington · Not yet recruiting
Research Site
Tacoma, Washington · Not yet recruiting
Research Site
Milwaukee, Wisconsin · Not yet recruiting
Research Site
Auchenflower, Australia · Withdrawn
Research Site
Ballarat, Australia · Not yet recruiting
Research Site
Clayton, Australia · Not yet recruiting
Research Site
Darlinghurst, Australia · Not yet recruiting
Research Site
Elizabeth Vale, Australia · Not yet recruiting
Research Site
South Brisbane, Australia · Not yet recruiting
Research Site
St Albans, Australia · Withdrawn
Research Site
Barretos, Brazil · Not yet recruiting
Research Site
Curitiba, Brazil · Not yet recruiting
Research Site
Salvador, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
Calgary, Alberta, Canada · Not yet recruiting
Research Site
Abbotsford British Columbia, British Columbia, Canada · Not yet recruiting
Research Site
Barrie, Ontario, Canada · Recruiting
Research Site
Hamilton, Ontario, Canada · Recruiting
Research Site
Kingston, Ontario, Canada · Not yet recruiting
Research Site
London, Ontario, Canada · Not yet recruiting
Research Site
Mississauga, Ontario, Canada · Not yet recruiting
Research Site
Montreal, Quebec, Canada · Not yet recruiting
Research Site
Montreal, Quebec, Canada · Not yet recruiting
Showing 40 of 160 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.